Related Experiment Video
Updated: Jul 17, 2026

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3
Published on: August 17, 2011
Sustained-release calcium channel antagonists in cardiovascular disease: pharmacology and current therapeutic use
F E Silvestry1, M G St John Sutton
1Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, USA.
Abstract:
Calcium channel antagonists are a heterogeneous group of drugs with differing cardiovascular effects, and are effective in the treatment of hypertension and angina pectoris. A number of these agents are available in a sustained-release formulation. These formulations produce a gradual and sustained drop in peripheral vascular resistance, thereby avoiding reflex sympathetic stimulation, and thus may avoid the deleterious effects that have been reported with short-acting preparations. The results of a number of trials with sustained-release calcium channel antagonists have been reported recently, and the results are promising. Currently they can be recommended for use in patients with hypertension or stable angina which cannot be controlled with other agents. They have been shown to be at least safe when used in patients with left ventricular systolic dysfunction, and may be useful in certain subsets of patients with heart failure. The empirical use of calcium channel antagonists in unstable angina and acute myocardial infarction is not supported by the currently available data. Several large trials with sustained-release formulations are ongoing, which may alter treatment recommendations in the future.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...

